Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - JAK2 Inhibitors

  • Companion Diagnostics: 52 Pick-Up
    ... development, and commercialization of therapeutic inhibitors for the cancer targets. ... diagnostic for use alongside Eli Lilly's JAK2 inhibitor blood cancers candidate, which ...
    5-9-2013
  • Studies Show JAK1/2 Inhibition Increases Tumor Cell Susceptibility...
    ... The team went on to confirm that shRNA-mediated JAK1 or JAK2 knockdown similarly increased ... And importantly, treating different cancer cell lines with small molecule JAK inhibitors ...
    6-12-2012
  • Cell Therapeutics Pays $30M in Cash and Stock for S*BIO's Selective...
    of red blood cell and platelet formation seen with pacritinib has the potential to satisfy a medical need not currently addressed with existing nonselective JAK1/JAK2 inhibitors." ...
    4-19-2012
  • Directing Cell-Signaling Research
    ... maturation, and so they're still candidates of Hsp90 inhibitors," Dr. Proia pointed out. Leukemic cell lines driven by JAK2 mutations are highly sensitive to ganetespib, due in ...
    11-1-2011
  • Mutations and Mechanisms Involved in Childhood T-Cell Acute Lymphoblas...
    ... constitutive STAT5 phosphorylation, JAK3, JAK2, and TYK2 were not activated by the IL7R ... of their findings by testing a number of JAK inhibitors on IL7R -mutant cell lines. ...
    9-6-2011
  • Small Molecule Simplicity Gives Them Staying Power
    Although there are four members in the JAK family of kinases, the company focused on developing selective JAK1 and JAK2 inhibitors based on its understanding that IL-6, a ...
    6-15-2011
  • Ambit Scores $30M to Advance Kinase Inhibitor Pipeline
    this compound, the companies will also work together on R&D of additional FLT3 inhibitors. ... AC430, an oral JAK2 inhibitor, is in Phase I trials in autoimmune diseases and lymphomas. ...
    6-10-2011
  • AmoyDx Gains CE Mark for EGFR, KRAS, and BRAF Tests
    These variations are associated with sensitivity to small molecule kinase inhibitors such ... AmoyDx offerings include kits for mutation status of JAK2, ABL, PIK3CA, KIT, PDGFRA, and ...
    2-25-2011
  • Sanofi-Aventis Acquires TargeGen and Inks Partnership with JDRF
    Sanofi-Aventis is taking over TargeGen, a developer of small molecule kinase inhibitors. ... The molecule is an oral, potent, and highly selective JAK2 kinase inhibitor, according to ...
    7-1-2010
  • S*BIO and Onyx Pharmaceuticals Expand JAK2 Inhibitor Partnership
    S*BIO and Onyx Pharmaceuticals expanded their development collaboration and option and license commercialization agreement for S*BIO's JAK2 inhibitors, SB1518 and SB1578, also ...
    5-5-2010
  • Ambit Has High Hopes for Kinase Screening Tool
    ... Many tumors show mutations in the BRAF kinase, including melanoma and colon tumors. Inhibitors of Aurora, JAK2, and CSF1R kinases are also in development for inflammatory diseases ...
    6-1-2009
  • Onyx Initially Pays $25M for Rights to S*BIO's JAK2 Inhibitors
    S*BIO will initially receive $25 million as a combination of cash and stock under a collaboration with Onyx Pharmaceuticals covering JAK2 inhibitors, SB1518 and SB1578. The total ...
    1-7-2009
  • Emerging Firms Highlighted at Roth Meeting
    ... platform, such as SGX523, a cMET kinase inhibitor currently in Phase I studies, BCR-ABL inhibitors being developed by SGX in partnership with Novartis, and JAK2 inhibitors. ...
    4-15-2008
  • More »

    Journal Articles

  • JAK2 V617F Mutation Prevalence in Myeloproliferative Neoplasms...
    Rafael Ramos da Silva, Betânia Lucena Domingues Hatzlhofer, Cíntia Gonsalves de Faria Machado, Aleide Santos de Melo Lima, Dulcinéia Martins de Albuquerque, Magnun Nueldo Nunes dos Santos, Kleber Yotsumoto Fertrin, Fernando Ferreira Costa, Aderson da Silva Araújo, Marcos Andre Cavalcanti Bezerra, Betania Lucena Domingues Hatzlhofer, Dulcineia Martins de Albuquerque, Aderson S Araujo
    Genetic Testing and Molecular Biomarkers
    Screening for JAK2 V617F may allow specific management of these diseases with JAK2 inhibitors in the future and highlights the need for further studies on the pathogenesis of ...
  • Hepatocyte Growth Factor Induces a Proangiogenic Phenotype and...
    Katrin Schröder, Susanne Schütz, Isabella Schlöffel, Sina Bätz, Ina Takac, Norbert Weissmann, U. Ruth Michaelis, Masamichi Koyanagi, Ralf P. Brandes
    Antioxidants & Redox Signaling
    of a STAT3 reporter construct was attenuated after downregulation of Nox2. Accordingly, the HGF-stimulated tube formation of HUVEC was blocked by inhibitors of Jak2 and Jnk. ...
  • Acquired Mutation of the Tyrosine Kinase JAK2V617F in Egyptian...
    Mona Wagdy Ayad, Dalia Nafea
    Genetic Testing and Molecular Biomarkers
    PV, PMF, RARS-T, and MDS/MPN group. The identification of JAK2V617F mutations has raised the prospect of developing specific JAK2V617F inhibitors to treat mutated patients.
  • Single Cell Network Profiling (SCNP): Mapping Drug and Target...
    Todd M. Covey, Santosh Putta, Alessandra Cesano
    ASSAY and Drug Development Technologies
    Abstract Measuring target coverage of small molecule inhibitors is paramount-first, for ... Jak2 vs. Jak3 selectivity as well as "off-target" effects on other cell signaling pathways ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll